Amgen (AMGN) Cash & Equivalents Growth (5y) (2014 - 2026)
Amgen (AMGN) Cash & Equivalents Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.52% |
| Dec 31, 2025 | 7.82% |
| Sep 30, 2025 | 0.78% |
| Jun 30, 2025 | -2.57% |
| Mar 31, 2025 | 2.76% |
| Dec 31, 2024 | 14.68% |
| Sep 30, 2024 | -4.62% |
| Jun 30, 2024 | 10.98% |
| Mar 31, 2024 | 5.70% |
| Dec 31, 2023 | 9.52% |
| Sep 30, 2023 | 23.78% |
| Jun 30, 2023 | 27.58% |
| Mar 31, 2023 | 26.50% |
| Dec 31, 2022 | 14.96% |
| Sep 30, 2022 | 25.93% |
| Jun 30, 2022 | 14.63% |
| Mar 31, 2022 | 14.22% |
| Dec 31, 2021 | 19.77% |
| Sep 30, 2021 | 27.99% |
| Jun 30, 2021 | 20.31% |